Chemomab Therapeutics Ltd. (CMMB) Stock Analysis & Investment Frameworks
Chemomab Therapeutics Ltd. (CMMB) stock analysis on Invetso. Review Chemomab Therapeutics Ltd.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Chemomab Therapeutics Ltd. Company Overview
- Exchange: NASDAQ Capital Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: IL
Chemomab Therapeutics Ltd. Key Financial Metrics
- Market Cap: $8.91M
- Revenue: $N/A
- ROE: -70.81%
- ROIC: -91.65%
- Dividend Yield: N/A
About Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd. operates as a clinical-stage biotechnology firm, dedicated to identifying and advancing novel treatments for inflammatory and fibrotic conditions. Its leading experimental drug candidate, CM-101, is a humanized monoclonal antibody specifically engineered to impede the core function of soluble chemokine CCL24. This potential therapy is currently under investigation for its efficacy in managing primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Established in 2011, the company, formerly known as Anchiano Therapeutics Ltd., adopted its current name, Chemomab Therapeutics Ltd., in March 2021 and is headquartered in Tel Aviv, Israel.
Chemomab Therapeutics Ltd. Investment Frameworks
Invetso analyzes Chemomab Therapeutics Ltd. (CMMB) across the following frameworks:
- Chemomab Therapeutics Ltd. 10Y Growth Potential
- Chemomab Therapeutics Ltd. Scenario Analysis
- Chemomab Therapeutics Ltd. Risks & Opportunities
- Chemomab Therapeutics Ltd. Economic Moat
- Chemomab Therapeutics Ltd. Business Model
- Chemomab Therapeutics Ltd. Management
- Chemomab Therapeutics Ltd. SWOT Analysis
- Chemomab Therapeutics Ltd. Porter's 5 Forces
- Chemomab Therapeutics Ltd. PESTLE Analysis
- Chemomab Therapeutics Ltd. ESG Analysis